JPM vs MBBC
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
JPM exhibits a concerning Piotroski F-Score of 2/9, indicating weak short-term fundamental health, and currently trades at a significant premium to both its Graham Number ($239.11) and Intrinsic Value ($140.07). While the company maintains a strong ROE of 16.13% and dominant market positioning, negative YoY earnings growth (-3.60%) and bearish insider activity from the CEO and CFO signal internal caution. The stock's current price of $313.68 suggests the market is pricing in a growth premium that is not currently supported by the deterministic health or value metrics.
MBBC presents a contradictory profile characterized by a stable Piotroski F-Score of 4/9 but significant valuation overstretch. While the company exhibits explosive year-over-year earnings growth (919.60%) and revenue growth (40.30%), the current price of $13.64 trades at a substantial premium to both its Graham Number ($10.38) and Intrinsic Value ($8.85). Fundamental efficiency remains weak with a very low ROE of 1.94%, and the technical trend is heavily bearish (10/100), suggesting a potential correction toward fair value despite the growth trajectory.
Compare Another Pair
Related Comparisons
JPM vs MBBC: Head-to-Head Comparison
This page compares JPMorgan Chase & Co. (JPM) and Marathon Bancorp, Inc. (MBBC) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.